ALXO
$2.17+0.10 (+4.57%)
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a ...
Recent News
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.
IBRX Stock Jumps on Progress in NK Cell Therapy Production
ImmunityBio stock gains more than 7% after completing two programs, showing scalable production of M-ceNK NK cells and early safety data in solid tumor patients.
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study
J&J reports phase I study win for Erda-iDRS in NMIBC, showing strong response rates, durable control and manageable safety as mid-to-late-stage studies advance.
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4
ALLO posts a narrower Q4 loss than expected, cuts expenses and advances key CAR-T studies, with cash projected to fund operations into 2028.
ALX Oncology initiated with a Buy at UBS
UBS initiated coverage of ALX Oncology (ALXO) with a Buy rating and $6 price target The company has a potential blockbuster program with a CD47 combo currently in Phase II for metastatic breast cancer, the analyst tells investors in a research note. UBS sees ALX reporting a “robust” dataset in mid-2027, demonstrating CD47 inhibitor evorpacept’s efficacy in CD47 high and/or HER2+ metastatic breast cancer patients. Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing t